Arch Dermatol Res. 2025 Jan 18;317(1):286. doi: 10.1007/s00403-025-03818-7.
ABSTRACT
Atherosclerosis, in which chronic inflammation is also effective in it’s pathogenesis, is an important cause of morbidity and mortality in psoriasis patients. Early diagnosis and management of atherosclerosis is important. Measurement of carotid intima media thickness is a method used to determine subclinical atherosclerosis. Our aim in this study is to evaluate subclinical atherosclerosis in psoriasis patients and to examine the effects of targeted therapies on atherosclerosis. This study included 105 psoriasis patients who applied to psoriasis outpatient clinic between May 2022 and December 2022. The patients’ age, gender, psoriasis area severity index (PASI) and the initiated treatment agent (topical treatment, sekukinumab, iksekizumab, guselkumab, risankizumab) were noted. Carotid intima-media thickness measurements were taken at baseline and after 6 months of treatment. In patients who were treated with secukinumab, ixekizumab, risankizumab, and guselkumab, there was a statistically significant decrease in catorid-intima media thickness at 6th month when compared with the baseline measurements (p = 0,002 p < 0,001 p < 0,001 p = 0,036 p < 0,001). On the other hand, an increase in the thickness was observed in the topical treatment group. According to our study results, targeted systemic treatments contribute to the improvement of subclinical atherosclerosis in psoriasis patients, while this effect was not seen in topical treatments. These results are consistent with literature data reporting that psoriasis is a systemic inflammatory disease.
PMID:39825924 | DOI:10.1007/s00403-025-03818-7
